Site Editor

Thomas Flaig, MD

Advertisement

Advertisement

News

Can Response to Palbociclib Therapy for Bladder Tumors Be Predicted by an In Vivo Imaging Biomarker?

Medical Literature

Improving Preoperative Treatment Plans in Bladder Cancer: Focus on Cystoscopic Parameters

News

ESMO 2022: Enfortumab Vedotin Plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Cancer

Medical Literature

Bladder Cancers With a Glandular Phenotype: Comparing Outcomes and Genomic Alteration Profiles

News

ESMO 2022: Can MRI-Based Staging of Newly Diagnosed Bladder Cancer Shorten the Time to Appropriate Treatment?

News

ESMO 2022: Can a Calculated Hypoxia Score Lead to Personalized Treatment in Bladder Cancer?

Medical Literature

Is Neoadjuvant Standard of Care for Muscle-Invasive Bladder Cancer Appropriate for Older Patients?

Monika Joshi, MD, on Findings on Chemoradiation With Durvalumab in Urothelial Carcinoma

Sumanta K. Pal, MD: Interpreting the Latest Results From the COSMIC-021 Study on Cabozantinib Plus Atezolizumab in Urothelial Carcinoma

View More

Advertisement

JNCCN Spotlights

Enfortumab Vedotin-ejfv

Sacituzumab Govitecan-hziy

View More

More

News

The Intersection of Self-Harm, Psychiatric Disorders, and Cancer Diagnoses

Phase III Trial to Combine Maintenance Avelumab and Cabozantinib in Metastatic Urothelial Cancer

Research Sheds Light on Molecular Mechanisms of Cisplatin-Resistant Bladder Cancer

ESMO 2022: Can a Calculated Hypoxia Score Lead to Personalized Treatment in Bladder Cancer?

ESMO 2022: Can MRI-Based Staging of Newly Diagnosed Bladder Cancer Shorten the Time to Appropriate Treatment?

Can ctDNA Status Determine Response to Treatment With Atezolizumab in Bladder Cancer?

ASCO 2022: What Is ‘Platinum Ineligibility’ in Patients With Metastatic Urothelial Cancer?

ASCO 2022: Can Cell-Free DNA Methylation Predict Chemotherapy Benefit in Bladder Cancer?

View More

Advertisement

Published

Medical Literature

Metastatic Urothelial Cancer: Does Prior Treatment Hinder the Effectiveness of Pembrolizumab Therapy?

Evaluating Risk-Aligned Bladder Cancer Surveillance Practices

Five-Gene Score Model Under Study in Predicting Outcomes in Bladder Cancer

Preclinical Study of Tumor Microenvironment in Bladder Cancer Offers Clues to Causes of Chemoresistance

View More

Ongoing

CE Activities

Data-driven Debates on the Evolving Bladder Cancer Landscape: Harnessing Novelty to Improve Outcomes

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Bladder Cancer

What's New for GU: Individualizing Genitourinary Cancer Treatment

Metastatic Urothelial Carcinoma: 2020 Multidisciplinary Molecular Tumor Board

View More

Available

Clinical Trials

Evaluating Cystectomy with Perioperative Pembrolizumab and Perioperative Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer

Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation

View More

Resources

For Your Patients

Bladder Cancer Advocacy Network

American Cancer Society

American Bladder Cancer Society

JNCCN: How To Manage Cancer Care During COVID-19 Pandemic

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2022 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.